EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer

Xiujuan Gui, Haizhu Chen iD, Jianli Zhao, Hongna Lai, Simin Luo, Jie Chai, Yangyang Cai, Wenjing Wu, Yinduo Zeng, Maojian Chen, Ying Wang, Herui Yao iD und 1 weitere

Therapeutic Advances in Medical Oncology · 2026-08 · 18

DOI: 10.1177/17588359261477589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 20.08.2026. Verfasst von Xiujuan Gui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-s…. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GuangDong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have revolutionized the treatment for HER2-positive and HER2-low metastatic breast cancer (MBC). However, the comparative efficacy, safety, and molecular predictors of response to various anti-HER2 ADCs remain limited.

Objectives

To evaluate real-world clinical outcomes, safety profiles, and genomic alterations associated with response to anti-HER2 ADCs in patients with HER2-positive or HER2-low MBC.

Design

Retrospective single-center cohort study.

Methods

Patients with HER2-positive or HER2-low MBC who received anti-HER2 ADCs (T-DXd, SHR-A1811, RC48, or T-DM1) between September 1, 2020, and September 1, 2024, were enrolled. Progression-free survival (PFS), overall survival, objective response rate (ORR), and safety were assessed. Targeted next-generation sequencing was performed to identify genomic correlates of response.

Results

A total of 322 patients were included, comprising 183 HER2-positive and 139 HER2-low cases. The ORR in the HER2-positive group and the HER2-low group were 32.8% versus 20.8%, respectively, and median PFS were 9.9 months versus 4.1 months. Median PFS in the T-DXd, SHR-A1811, RC48, and T-DM1 groups were 9.3 months, 25.8 months, 3.2 months, and 7.6 months, respectively (p

Schlagwörter

Stichwörter der Autor:innen

HER2-lowHER2-positiveantibody-drug conjugatesgenomic alterationsmetastatic breast cancer

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Phase I Clinical Trial Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Haizhu Chen, Herui Yao, Linxiaoxiao Ding

Förderung

  • GuangDong Basic and Applied Basic Research Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Gui, X., Chen, H., Zhao, J., Lai, H., Luo, S., Chai, J., Cai, Y., Wu, W., Zeng, Y., Chen, M., Wang, Y., Yao, H., & Ding, L. (2026). Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261477589

Vancouver

Gui X, Chen H, Zhao J, Lai H, Luo S, Chai J, et al. Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261477589

BibTeX
@article{Gui2026,
  author = {Gui, Xiujuan and Chen, Haizhu and Zhao, Jianli and Lai, Hongna and Luo, Simin and Chai, Jie and Cai, Yangyang and Wu, Wenjing and Zeng, Yinduo and Chen, Maojian and Wang, Ying and Yao, Herui and Ding, Linxiaoxiao},
  title = {Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261477589}
}
Kostenlos starten →